Esophageal Cancer Clinical Trial
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Summary
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of one of the following advanced (unresectable and/or metastatic) solid tumors, documented by histopathology or cytopathology:
Hepatocellular carcinoma (HCC)
Colorectal cancer (CRC) (non-microsatellite instability-high [non-MSI-H]/deficient mismatch repair [dMMR])
Pancreatic ductal adenocarcinoma (PDAC).
Biliary tract cancer (BTC) (includes intrahepatic, extrahepatic cholangiocarcinoma [CCA] and gall bladder cancer)
Endometrial cancer (EC)
Esophageal squamous cell carcinoma (ESCC)
Disease progression on or since the most recent treatment (does not apply to newly diagnosed unresectable or metastatic HCC or EC).
Measurable disease per RECIST v1.1 as assessed locally (by investigator) and verified by BICR
Submission of an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
Male participants are abstinent from heterosexual intercourse or agree to follow contraceptive guidance during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib
Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP), or is a WOCBP and agrees to follow contraceptive guidance during the intervention period and and for at least 120 days after the last dose of pembrolizumab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last
Adequate organ function
Adequately controlled blood pressure with or without antihypertensive medications
HCC Specific Inclusion Criteria: No prior systemic chemotherapy, including anti-VEGF therapy, anti-programmed cell-death (PD-1)/immunotherapy-drugs-are-boosting-survival/" >PD-L1 or any systemic investigational anticancer agents for advanced/unresectable HCC (1L)
CRC ([non-MSI-H/dMMR) Specific Inclusion Criteria: Received at least 2 prior lines of systemic therapy for unresectable or metastatic disease which includes fluoropyrimidine, irinotecan and oxaliplatin
PDAC Specific Inclusion Criteria: Prior therapy with at least 1 (platinum or gemcitabine containing regimen) but no more than 2 prior systemic therapies for unresectable or metastatic pancreatic cancer
BTC Specific Inclusion Criteria: Received at least 1 prior line of systemic therapy (containing gemcitabine or fluoropyrimidine) for unresectable or metastatic disease
EC Specific Inclusion Criteria: Study treatment is for 1L therapy of EC and participants should not have received prior systemic chemotherapy. Exception: May have received 1 prior line of line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of a curative-intent resection, if the recurrence occurred ≥6 months after the last dose of chemotherapy or may have received prior radiation with or without chemotherapy
ESCC Specific Inclusion Criteria: Have experienced radiographic or clinical progression on one prior line of standard systemic therapy (immune oncology (IO) naïve participants) or an anti-PD-1/PD-L1 (IO resistant participants)
Exclusion Criteria:
Unable to swallow orally administered medication or presence of a gastrointestinal (GI) disorder that may affect study intervention absorption
History of a second malignancy that is progressing or has required active treatment within 3 years
A pulse oximeter reading <92% at rest, or requirement of intermittent supplemental oxygen/ chronic supplemental oxygen
Presence of central nervous system (CNS) metastases and/or carcinomatous meningitis
Clinically significant cardiovascular disease within 6 months of first dose of study intervention
Symptomatic pleural effusion, unless clinically stable after treatment
Preexisting ≥ Grade 3 gastrointestinal (GI) or non-GI fistula
Moderate to severe hepatic impairment
Clinically significant history of bleeding within 3 months before screening
Presence of serious active nonhealing wound/ulcer/bone fracture
Requirement for hemodialysis or peritoneal dialysis
History of human immunodeficiency virus (HIV) infection
History of Hepatitis B or active Hepatis C virus infections. with exceptions for HCC and BTC
Prior therapy with a PD-1, anti-PD-L1, anti-PD-L2 agent, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) or hypoxia-inducible factor 2α (HIF-2α)
Radiographic evidence of intratumoral cavitation, or invasion/infiltration of a major blood vessel
EC specific exclusion criteria: History of carcinosarcoma, endometrial leiomyosarcoma or other high-grade sarcomas, or endometrial stromal sarcomas
ESCC specific exclusion criteria: Has clinically apparent ascites or pleural effusion or experienced weight loss >20% over approximately 3 months before first dose of study therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 54 Locations for this study
Tucson Arizona, 85724, United States More Info
Duarte California, 91010, United States
San Francisco California, 94158, United States More Info
New Haven Connecticut, 06510, United States More Info
Washington District of Columbia, 20016, United States More Info
Gainesville Florida, 32610, United States More Info
Baltimore Maryland, 21287, United States More Info
New York New York, 10065, United States
Houston Texas, 77030, United States More Info
Madison Wisconsin, 53792, United States More Info
Westmead New South Wales, 2145, Australia More Info
Epping Victoria, 3076, Australia More Info
Malvern Victoria, 3144, Australia More Info
Brussels Bruxelles-Capitale, Region De, 1200, Belgium More Info
Yvoir Namur, 5530, Belgium More Info
Rennes Bretagne, 35042, France More Info
Brest Finistere, 29200, France More Info
La Tronche Isere, 38700, France More Info
Avignon Vaucluse, 84918, France More Info
Hwasun Gun Jeonranamdo, 58128, Korea, Republic of More Info
Daegu Taegu-Kwangyokshi, 42601, Korea, Republic of More Info
Seoul , 03080, Korea, Republic of More Info
Seoul , 03722, Korea, Republic of More Info
Seoul , 06351, Korea, Republic of More Info
Leiden Zuid-Holland, 2333 , Netherlands More Info
Utrecht , 3584 , Netherlands More Info
Grafton Auckland, 1023, New Zealand More Info
Oviedo Asturias, 33011, Spain More Info
Badalona Barcelona, 08916, Spain More Info
Madrid Madrid, Comunidad De, 28007, Spain More Info
How clear is this clinincal trial information?